Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.81 | N/A | +19.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.81 | N/A | +19.87% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on earnings performance while remaining non-committal about future revenue expectations.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing projects but did not offer specific guidance for the future.
Ligand Pharmaceuticals reported a strong earnings per share, beating expectations by nearly 20%. However, the lack of revenue figures and guidance may leave investors cautious. The stock reacted positively, rising slightly by 0.52%, reflecting investor approval of the EPS surprise.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MICROCHIP TECHNOLOGY
Aug 3, 2015